NCT05263895 - Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

May 16, 2022

Study Completion Date

May 16, 2022

Conditions

Bioavailability

Interventions

DRUG

PF-07321332/ritonavir

PF-07321332 ritonavir will be administered as single dose orally

DRUG

PF-07321332/ritonavir

PF-07321332 ritonavir will be administered as single oral dose orally.

DRUG

PF-07321332/ritonavir

PF-07321332 ritonavir will be administered as single oral dose orally.

DRUG

PF-07321332/ritonavir

PF-07321332 ritonavir will be administered as single oral dose orally.

DRUG

PF-07321332

PF-07321332 will be administered as single oral dose orally.

Trial Locations (1)

Pfizer Clinical Research Unit - New Haven, New Haven